# THERAPEUTIC TARGET EVIDENCE SUMMARY REPORT

## 1. Executive Summary
TP53 encodes a protein-coding transcription factor (“Cellular tumor antigen p53”) that is extensively characterized in human biology and oncology. Target annotation from Pharos classifies TP53 as Tchem, with 14 annotated ligands, very low novelty (1.907e-05), and family designation “TF.” These attributes collectively indicate a well-studied target with established small-molecule interactions and broad prior characterization. Across independent disease-mapping resources, TP53 is consistently and strongly associated with a wide spectrum of malignancies and a hereditary cancer predisposition syndrome.

Large-scale functional genomics data from DepMap (CRISPR Gene Effect, DepMap 25Q3) indicate that TP53 knockout is not broadly essential for in vitro tumor cell viability, with a global CRISPR gene effect raw_value of 0.3709969930537301 across 1,168 cell lines, only 4 of which meet a strong dependency threshold (gene effect ≤ −0.5; strong_dependency_fraction = 0.0034). Nevertheless, a small subset of cell lines demonstrate stronger negative gene-effect scores (e.g., ACH-002030 gene_effect = −0.9196145595707584), evidencing context-specific dependencies or liabilities in limited cellular backgrounds.

Open Targets disease associations (n = 15 extracted of 3,277 total TP53–disease associations reported by the platform) display high quantitative support across diverse neoplasms and hereditary syndromes. Scores range from 0.876057126143572 for Li-Fraumeni syndrome to 0.6940585984302623 for urinary bladder cancer, with consistent tractability flags (“SM: Druggable Family,” “PR: Small Molecule Binder,” “OC: Advanced Clinical”) supporting the existence of drug-binding evidence and clinically advanced modalities relevant to the target or its modulation strategies.

The literature corpus reflects exceptional volume and impact: 15 top-ranked publications related to TP53 retrieved from Europe PMC span seminal cancer genomics initiatives, clinical guidelines, and foundational method resources, with citation counts as high as 11,732 (PMID:23550210). This breadth and depth of literature confirm the centrality of TP53 in cancer biology, cohort-scale genomics, and translational frameworks.

Overall, the evidence converges on TP53 as: (1) a deeply characterized, ligandable transcription factor; (2) not broadly essential for cancer cell survival in CRISPR knockout screens, though with rare strong dependencies; (3) robustly and pervasively associated with numerous cancers and a canonical hereditary cancer syndrome; and (4) supported by an extensive, highly cited scientific literature. The integrated readout points to strong disease relevance and pharmacological tractability signals, counterbalanced by limited direct dependency in unstratified tumor cell line populations.

Executive summary evidence overview:
| Source        | Status  | Item count | Notes                                              |
|---------------|---------|------------|----------------------------------------------------|
| depmap        | success | 15         | 1 global CRISPR gene effect + 14 top cell-line items (DepMap 25Q3) |
| pharos        | success | 1          | Target annotation (Tchem; TF family; ligands=14; novelty=1.907e-05) |
| opentargets   | success | 15         | 15 TP53–disease associations (of 3,277 total OT associations) |
| literature    | success | 15         | 15 top-ranked Europe PMC items (citations up to 11,732) |


## 2. Target Annotation Evidence
The Pharos target annotation identifies TP53 as “Cellular tumor antigen p53,” classed within the transcription factor (TF) family and assigned the Target Development Level (TDL) of Tchem. The annotation reports 14 ligands and an extremely low novelty metric (1.907e-05), reflecting extensive prior characterization. No top diseases are listed in the Pharos annotation record here, which is consistent with Pharos’ role as a target-centric registry rather than a disease-association catalog. The normalized_score provided for the annotation is 0.8200000000000001, with confidence 0.728, indicating high-quality, curated target-level information. This annotation supports pharmacologic tractability by cataloging small-molecule interactions with TP53 and situates the target within a well-studied class.

Target annotation summary:
| Field                         | Value                                                                 |
|------------------------------|-----------------------------------------------------------------------|
| Target symbol                | TP53                                                                  |
| Target name                  | Cellular tumor antigen p53                                            |
| Family                       | TF                                                                    |
| Target Development Level     | Tchem                                                                 |
| Ligand total                 | 14                                                                    |
| Novelty                      | 1.907e-05                                                             |
| Disease association count    | 0                                                                     |
| Top diseases                 | []                                                                    |
| Normalized score             | 0.8200000000000001                                                    |
| Confidence                   | 0.728                                                                 |
| Source                       | Community Pharos MCP (Cloudflare Workers)                             |
| Summary (source-provided)    | [ext] Pharos target annotation: TP53 TDL=Tchem, ligands=14, family=TF, disease_association_count=0. |


## 3. Genetic Dependency Evidence

### Global Dependency Analysis
DepMap CRISPR gene-effect profiling (DepMap 25Q3) across 1,168 cell lines reports a TP53 gene effect raw_value of 0.3709969930537301, with normalized_score 0.3763343356487567 and confidence 0.801027397260274. In DepMap CRISPR datasets, negative gene-effect values reflect dependency (lower values indicate greater essentiality). The positive aggregate gene-effect estimate here is consistent with a lack of broad essentiality for TP53 in vitro; only 4 of 1,168 lines meet the strong-dependency threshold (≤ −0.5), yielding a strong_dependency_fraction of 0.0034. The average_gene_effect field in support (0.371) mirrors the global raw_value summary. Together, these findings indicate limited direct viability dependency on TP53 across unselected cancer cell lines, while leaving room for specific molecular contexts that may yield dependency phenotypes (as evidenced by the outlier cell lines in the next subsection).

DepMap global gene-effect metrics for TP53:
| Metric                          | Value                         |
|---------------------------------|-------------------------------|
| Gene effect (raw_value)         | 0.3709969930537301            |
| Normalized score                | 0.3763343356487567            |
| Confidence                      | 0.801027397260274             |
| Cell line count                 | 1168                          |
| Average gene effect (support)   | 0.371                         |
| Strong dependency count (≤ −0.5)| 4                             |
| Strong dependency fraction      | 0.0034                        |
| Column name                     | TP53 (7157)                   |
| Screen type                     | CRISPRGeneEffect              |
| Data release                    | DepMap 25Q3                   |
| Provider                        | DepMap (Broad Institute)      |
| Summary (source-provided)       | DepMap CRISPR gene effect for TP53: 0.371 avg across 1168 cell lines (4 show strong dependency ≤ −0.5). |

### Top Dependent Cell Lines
While TP53 is not broadly essential across cell lines, a subset shows more negative gene-effect values indicating potential dependency. The top 14 lines by rank_within_gene display gene_effect values ranging from −0.9196145595707584 to −0.3086482882316889, with corresponding high normalized_score and confidence values. These observations support heterogeneity in dependency profiles and suggest that specific cellular or genetic contexts may condition TP53-linked vulnerabilities.

Top-ranked TP53 cell-line dependencies (CRISPR Gene Effect, DepMap 25Q3):
| Rank within gene | Cell line ID | Gene effect (raw_value)    | Normalized score         | Confidence              | Screen type       | Data release  |
|------------------|--------------|----------------------------|--------------------------|-------------------------|-------------------|---------------|
| 1                | ACH-002030   | −0.9196145595707584        | 0.8065381865235861       | 0.880980727978538       | CRISPRGeneEffect  | DepMap 25Q3   |
| 2                | ACH-000374   | −0.7652299064426166        | 0.7550766354808722       | 0.8732614953221308      | CRISPRGeneEffect  | DepMap 25Q3   |
| 3                | ACH-002664   | −0.6305054533674547        | 0.7101684844558181       | 0.8665252726683728      | CRISPRGeneEffect  | DepMap 25Q3   |
| 4                | ACH-000294   | −0.5555590841328759        | 0.6851863613776253       | 0.8627779542066438      | CRISPRGeneEffect  | DepMap 25Q3   |
| 5                | ACH-001322   | −0.4600877768740278        | 0.6533625922913426       | 0.8580043888437014      | CRISPRGeneEffect  | DepMap 25Q3   |
| 6                | ACH-001310   | −0.4584620679408898        | 0.6528206893136299       | 0.8579231033970445      | CRISPRGeneEffect  | DepMap 25Q3   |
| 7                | ACH-001715   | −0.4307581082836105        | 0.6435860360945368       | 0.8565379054141806      | CRISPRGeneEffect  | DepMap 25Q3   |
| 8                | ACH-000890   | −0.390053674431259         | 0.6300178914770863       | 0.854502683721563       | CRISPRGeneEffect  | DepMap 25Q3   |
| 9                | ACH-002280   | −0.3273902908023196        | 0.6091300969341066       | 0.851369514540116       | CRISPRGeneEffect  | DepMap 25Q3   |
| 10               | ACH-000605   | −0.3193914918603819        | 0.6064638306201273       | 0.8509695745930191      | CRISPRGeneEffect  | DepMap 25Q3   |
| 11               | ACH-000402   | −0.3168974235117752        | 0.6056324745039251       | 0.8508448711755888      | CRISPRGeneEffect  | DepMap 25Q3   |
| 12               | ACH-000263   | −0.3159498791644104        | 0.6053166263881368       | 0.8507974939582206      | CRISPRGeneEffect  | DepMap 25Q3   |
| 13               | ACH-000030   | −0.3153029432934939        | 0.6051009810978313       | 0.8507651471646748      | CRISPRGeneEffect  | DepMap 25Q3   |
| 14               | ACH-000415   | −0.3086482882316889        | 0.6028827627438963       | 0.8504324144115845      | CRISPRGeneEffect  | DepMap 25Q3   |


## 4. Disease Association Evidence
Open Targets reports robust, high-scoring associations between TP53 and numerous malignancies as well as Li-Fraumeni syndrome. The extracted set (n = 15) spans association scores from 0.876057126143572 to 0.6940585984302623, with confidence metrics between 0.9128171378430716 and 0.8582175795290787. For all entries, support metadata include an association_count of 3,277 for TP53 overall, reflecting the extensive network of TP53–disease relationships curated by the platform. Tractability flags consistently indicate “SM: Druggable Family,” “PR: Small Molecule Binder,” and “OC: Advanced Clinical,” supporting the feasibility of small-molecule or binder-based modalities with clinical advancement relevant to TP53 biology.

Open Targets TP53–disease associations (subset of 15; association_count for TP53 overall = 3,277):
| Rank | Disease name                                       | Disease ID           | Association score       | Confidence              | Tractability SM        | Tractability PR           | Tractability OC       |
|------|----------------------------------------------------|----------------------|-------------------------|-------------------------|------------------------|----------------------------|-----------------------|
| 1    | Li-Fraumeni syndrome                               | MONDO_0018875        | 0.876057126143572       | 0.9128171378430716      | Druggable Family       | Small Molecule Binder      | Advanced Clinical     |
| 2    | hepatocellular carcinoma                           | EFO_0000182          | 0.7963784748427343      | 0.8889135424528203      | Druggable Family       | Small Molecule Binder      | Advanced Clinical     |
| 3    | head and neck squamous cell carcinoma              | EFO_0000181          | 0.7771265372974727      | 0.8831379611892418      | Druggable Family       | Small Molecule Binder      | Advanced Clinical     |
| 4    | Hereditary breast cancer                           | Orphanet_227535      | 0.7431566565221103      | 0.8729469969566331      | Druggable Family       | Small Molecule Binder      | Advanced Clinical     |
| 5    | hereditary breast carcinoma                        | MONDO_0016419        | 0.7426121638298758      | 0.8727836491489628      | Druggable Family       | Small Molecule Binder      | Advanced Clinical     |
| 6    | colorectal cancer                                  | MONDO_0005575        | 0.7362135364037248      | 0.8708640609211175      | Druggable Family       | Small Molecule Binder      | Advanced Clinical     |
| 7    | lung adenocarcinoma                                | EFO_0000571          | 0.729249967981865       | 0.8687749903945595      | Druggable Family       | Small Molecule Binder      | Advanced Clinical     |
| 8    | esophageal cancer                                  | MONDO_0007576        | 0.7280857297437422      | 0.8684257189231227      | Druggable Family       | Small Molecule Binder      | Advanced Clinical     |
| 9    | choroid plexus papilloma                           | MONDO_0009837        | 0.7240247772760406      | 0.8672074331828122      | Druggable Family       | Small Molecule Binder      | Advanced Clinical     |
| 10   | acute myeloid leukemia                             | EFO_0000222          | 0.7236206490426432      | 0.867086194712793       | Druggable Family       | Small Molecule Binder      | Advanced Clinical     |
| 11   | bone marrow failure syndrome                       | MONDO_0000159        | 0.7200478237739412      | 0.8660143471321824      | Druggable Family       | Small Molecule Binder      | Advanced Clinical     |
| 12   | bone osteosarcoma                                  | MONDO_0002629        | 0.7117775561933679      | 0.8635332668580104      | Druggable Family       | Small Molecule Binder      | Advanced Clinical     |
| 13   | breast adenocarcinoma                              | EFO_0000304          | 0.7084289980323472      | 0.8625286994097042      | Druggable Family       | Small Molecule Binder      | Advanced Clinical     |
| 14   | nasopharyngeal carcinoma                           | MONDO_0015459        | 0.6955292671403202      | 0.8586587801420961      | Druggable Family       | Small Molecule Binder      | Advanced Clinical     |
| 15   | urinary bladder cancer                              | MONDO_0001187        | 0.6940585984302623      | 0.8582175795290787      | Druggable Family       | Small Molecule Binder      | Advanced Clinical     |


## 5. Literature Evidence
The literature landscape surrounding TP53 is voluminous and heavily cited, underscoring seminal roles in cancer biology, large-scale genomic characterizations, and methodological platforms. The extracted top 15 items from Europe PMC (query: “TP53”) include landmark cohort studies (e.g., TCGA breast, colorectal, ovarian, glioblastoma), pan-cancer initiatives, high-impact methodological resources (e.g., cBioPortal, IGV, QuPath), and authoritative clinical/WHO guidelines. Citation counts range from 5,888 to 11,732, with most items reflecting high influence and pervasive utility across oncology research and clinical translation.

Top TP53-related literature (Europe PMC):
| Rank | PMID     | Title                                                                                                                                                                                                                  | Pub year | Cited by count (raw_value) | Normalized score | Confidence | Query   |
|------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|----------------------------|------------------|------------|---------|
| 1    | 23550210 | Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.                                                                                                                            | 2013     | 11732                      | 1.0              | 0.85       | "TP53"  |
| 2    | 23000897 | Comprehensive molecular portraits of human breast tumours.                                                                                                                                                             | 2012     | 9406                       | 1.0              | 0.85       | "TP53"  |
| 3    | 26462967 | 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. | 2016     | 9349                       | 1.0              | 0.85       | "TP53"  |
| 4    | 20303878 | Immunity, inflammation, and cancer.                                                                                                                                                                                    | 2010     | 7915                       | 1.0              | 0.85       | "TP53"  |
| 5    | 11553815 | Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.                                                                                                                  | 2001     | 7640                       | 1.0              | 0.85       | "TP53"  |
| 6    | 34185076 | The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.                                                                                                                                        | 2021     | 7621                       | 1.0              | 0.85       | "TP53"  |
| 7    | 23945592 | Signatures of mutational processes in human cancer.                                                                                                                                                                    | 2013     | 7506                       | 1.0              | 0.85       | "TP53"  |
| 8    | 32029601 | The biology<b>,</b> function<b>,</b> and biomedical applications of exosomes.                                                                                                                                          | 2020     | 7051                       | 1.0              | 0.85       | "TP53"  |
| 9    | 22517427 | Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration.                                                                                                                      | 2013     | 7041                       | 1.0              | 0.85       | "TP53"  |
| 10   | 22810696 | Comprehensive molecular characterization of human colon and rectal cancer.                                                                                                                                             | 2012     | 6579                       | 1.0              | 0.85       | "TP53"  |
| 11   | 29203879 | QuPath: Open source software for digital pathology image analysis.                                                                                                                                                      | 2017     | 6274                       | 1.0              | 0.85       | "TP53"  |
| 12   | 22460905 | The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.                                                                                                                         | 2012     | 6210                       | 1.0              | 0.85       | "TP53"  |
| 13   | 24071849 | The Cancer Genome Atlas Pan-Cancer analysis project.                                                                                                                                                                   | 2013     | 6105                       | 0.9500000000000001 | 0.85    | "TP53"  |
| 14   | 21720365 | Integrated genomic analyses of ovarian carcinoma.                                                                                                                                                                      | 2011     | 5978                       | 0.9              | 0.85       | "TP53"  |
| 15   | 18772890 | Comprehensive genomic characterization defines human glioblastoma genes and core pathways.                                                                                                                             | 2008     | 5888                       | 0.8500000000000001 | 0.8     | "TP53"  |


## 6. Integrated Evidence Interpretation
Converging evidence assigns TP53 a central role in oncogenesis and hereditary cancer predisposition. Open Targets association scores are uniformly high across a spectrum of solid and hematologic malignancies and Li-Fraumeni syndrome, consistent with a pervasive biological link between TP53 status and disease phenotypes. The uniform tractability tags across diseases (Druggable Family, Small Molecule Binder, Advanced Clinical) suggest that pharmacological interventions targeting TP53 or its binding interfaces have been sufficiently explored to reach advanced stages in the development continuum.

Pharos annotation corroborates a well-established target profile: Tchem classification, transcription factor family designation, 14 reported ligands, and extremely low novelty (1.907e-05). These data are aligned with the concept of TP53 as a long-standing focus of chemical biology and translational research. The presence of multiple ligands reinforces the feasibility of small-molecule or binder-based interactions with TP53, complementing the tractability signals from Open Targets.

In contrast, DepMap functional genomics show that TP53 is not broadly essential for the in vitro survival of unstratified cancer cell lines, as reflected by a positive global gene effect (0.3709969930537301) and a very low fraction of strong dependencies (0.0034). This observation is consistent with the biological role of TP53 as a tumor suppressor; loss-of-function may not compromise, and in many contexts may even enhance, clonal fitness under in vitro conditions. Nonetheless, the identification of a small subset of cell lines with more negative gene effects (e.g., −0.9196145595707584 to −0.3086482882316889) indicates that, in certain molecular backgrounds, reduced TP53 function can be deleterious, reflecting context-specific liabilities.

The literature corpus provides foundational and translational context for these findings. High-impact publications encompassing cancer genomics atlases, pan-cancer analyses, disease-specific molecular portraits, and widely used analytic platforms show that TP53 is at the nexus of cancer classification, biomarker definition, and clinical guideline formation. The citation counts (up to 11,732) confirm that TP53 research is influential and integrative, spanning bench-to-bedside workflows. This breadth of literature supports the disease association findings and helps contextualize the functional genomics data within broader biological and clinical frameworks.


## 7. Evidence Strength Assessment
Target annotation evidence strength: Strong. The Pharos annotation shows high-confidence target-level curation (confidence 0.728; normalized_score 0.8200000000000001), with clear TF family placement, TDL of Tchem, 14 ligands, and very low novelty (1.907e-05). These metrics indicate a mature knowledge base and prior success in identifying small-molecule interactions with TP53. The absence of listed top diseases in the Pharos excerpt does not detract from the core target annotation robustness.

Genetic dependency evidence strength: Moderate-to-strong internal validity with limited positive signal. The DepMap dataset is extensive (1,168 cell lines, DepMap 25Q3) with a global gene-effect raw_value of 0.3709969930537301, normalized_score 0.3763343356487567, and confidence 0.801027397260274. The very low strong_dependency_fraction (0.0034; 4 of 1,168) argues against broad essentiality. However, the identification of a small number of more negatively scoring cell lines (e.g., −0.9196145595707584, −0.7652299064426166, −0.6305054533674547) highlights credible, context-specific dependencies. Overall, while the dataset quality and size lend strength, the therapeutic inference for direct suppression or loss-of-function targeting of TP53 is limited by the aggregate non-dependency signal.

Disease association evidence strength: Strong. Fifteen high-confidence associations from Open Targets demonstrate consistently high quantitative support (0.876057126143572 to 0.6940585984302623) across a diverse disease spectrum, including Li-Fraumeni syndrome and multiple cancer types. Confidence values range from 0.9128171378430716 to 0.8582175795290787. The platform-wide TP53 association_count of 3,277 further indicates comprehensive evidence integration. The recurrence of tractability labels (Druggable Family, Small Molecule Binder, Advanced Clinical) adds translational weight.

Literature evidence strength: Very strong. The Europe PMC results include landmark, heavily cited works (5,888 to 11,732 citations) spanning clinical guidelines, pan-cancer genomics, disease-specific molecular portraits, and core bioinformatic tools. The consistency of high-impact references corroborates the biological centrality and clinical relevance of TP53 and supports the disease association findings while contextualizing the dependency data.

Cross-category coherence: High. Target annotation and disease association data are fully coherent and strongly reinforced by the literature corpus. Genetic dependency data, though internally robust, introduce an important nuance: broad direct cell-lethal dependency on TP53 is not supported, consistent with TP53’s role and the biology of tumor suppressors in vitro. This nuance should shape therapeutic hypotheses toward modulation/restoration strategies or pathway-level interventions rather than broad loss-of-function targeting.


## 8. Overall Target Assessment
The assembled evidence positions TP53 as a pivotal, extensively characterized target with pervasive disease relevance and demonstrable tractability signals. Pharos and Open Targets collectively argue that TP53 is both biologically central and pharmacologically approachable (Tchem; ligands=14; “SM: Druggable Family,” “PR: Small Molecule Binder,” “OC: Advanced Clinical”). The literature strongly substantiates TP53’s role across diverse cancers and hereditary predisposition, providing a rich foundation for hypothesis generation and translational development.

From a functional genomics standpoint, DepMap indicates that direct ablation of TP53 does not produce broad cytotoxic dependency across unselected cancer cell lines, with only a small fraction exhibiting strong negative gene-effects. This observation is consistent with TP53’s canonical tumor suppressor role and suggests that therapeutic strategies relying on direct gene knockout-like effects are unlikely to yield generalized anti-tumor efficacy. Instead, the evidence supports pursuit of context-specific strategies or modalities that engage TP53 biochemistry in ways compatible with its biological role and the tractability indicators (e.g., small-molecule binding or clinically advanced modalities flagged by Open Targets).

Strategically, the high disease association scores and the overwhelming literature support argue that TP53-centric approaches remain clinically meaningful, particularly in settings anchored to genotype/phenotype linkages (e.g., hereditary syndromes and tumor subtypes with characteristic TP53 biology). The limited dependency signal in cell lines should be interpreted as guidance for modality selection and patient stratification rather than a negation of therapeutic potential.


## 9. Final Evidence-Based Conclusion
TP53 is a protein-coding transcription factor with extensive prior characterization and pharmacologic tractability indicators (Tchem classification; 14 ligands; Open Targets tractability flags including “Small Molecule Binder” and “Advanced Clinical”). Disease association evidence from Open Targets demonstrates consistently high scores across multiple cancers and Li-Fraumeni syndrome (0.876057126143572 to 0.6940585984302623; TP53 association_count = 3,277), firmly establishing clinical and biological relevance. The literature corpus is exceptionally strong, with highly cited works that shape modern cancer genomics, clinical guidelines, and analytic infrastructure.

DepMap functional genomics (CRISPR Gene Effect, 1,168 lines; global raw_value 0.3709969930537301; strong_dependency_fraction 0.0034) indicate that TP53 is not broadly essential for tumor cell viability in vitro, with only a small subset of cell lines displaying strong negative gene effects. This pattern is concordant with TP53’s tumor suppressor role and suggests that therapeutic strategies should emphasize context-specific modulation, restoration, or pathway-aligned approaches rather than universal dependency-based cytotoxic targeting.

In sum, the integrated evidence supports TP53 as a high-relevance, tractable target with substantial clinical and biological grounding, best approached through strategies that align with its biology and the observed dependency landscape.